Jazz Pharmaceuticals and Zymeworks announced positive topline phase 3 results for Ziihera in HER2-positive GEA. Click here to ...

Libtayo plus chemotherapy is potentially more cost-effective than Keytruda plus chemotherapy for advanced NSCLC, offering lower costs and higher QALYs. The study's model, based on clinical trial data, ...

On November 17, 2025, Jazz Pharmaceuticals announced that its Phase 3 HERIZON-GEA-01 trial showed Ziihera (zanidatamab-hrii) combined with chemotherapy, with or without the PD-1 inhibitor tislelizumab ...

A new study shows that by combining different chemotherapy drugs, testicular cancer remains highly treatable and often curable, even after first-line treatment fails. The recent study published in the ...

The chemotherapy-antibody combinations, known as antibody drug conjugates, have been described as both heat-seeking missiles and Trojan horses for cancer cells, designed to specifically home in on a ...

Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in ...

A naturally-occurring protein that tends to be expressed at higher levels in breast cancer cells boosts the effectiveness of ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today noted that our partner, Akeso, Inc. ("Akeso, ...

In a wholly new approach to cancer treatment, Northwestern University biomedical engineers have doubled the effectiveness of chemotherapy in animal experiments. Instead of attacking cancer directly, ...